TY - JOUR
T1 - Long-term effect of fulvestrant for locally advanced breast cancer in an elderly patient - A case report
AU - Sakurai, Kenichi
AU - Fujisaki, Shigem
AU - Kubota, Hitomi
AU - Hara, Yukiko
AU - Suzuki, Shuhei
AU - Adachi, Keita
AU - Tomita, Ryouichi
AU - Enomoto, Katsuhisa
AU - Hirano, Tomohiro
N1 - Publisher Copyright:
© 2018 Japanese Journal of Cancer and Chemotherapy Publishers Inc. All rights reserved.
PY - 2018/1
Y1 - 2018/1
N2 - We report an elderly patient with locally advanced breast cancer who received long-term fulvestrant therapy. The patient was a 75-year-old woman who presented with a right breast lump. She noticed the tumor 4 years and 6 months ago, but she had not visited any hospital. However, her daughter brought her to our hospital. The tumor was 73 mm in diameter. A core needle biopsy for breast tumor led to a diagnosis of an invasive ductal carcinoma, positive for estrogen receptor (ER) and progesterone receptor (PgR), and negative for HER2/neu. The Ki-67 positive cell index was 20%. We performed a wholebody checkup, and confirmed the diagnosis as T4cN1M0, Stage IB. She initiated endocrine therapy by letrozole (2.5 mg/day). After 1 year and 6 months, tumor marker levels increased. We changed the endocrine therapy to fulvestrant (500 mg/month). For the next 2 years and 6 months, this therapy was effective. Her axillary lymph node metastases disappeared and tumor size decreased (60%). She underwent muscle-preserving mastectomy plus axillary lymph node dissection. The pathological diagnosis from the resected surgical specimen was confirmed as invasive ductal carcinoma, positive for ER and PgR, and negative for HER2/neu protein expression. The surgical margins were negative, and there was no metastasis in the lymph nodes. She was administered adjuvant endocrine therapy. Four years after surgery, she was well without metastasis.
AB - We report an elderly patient with locally advanced breast cancer who received long-term fulvestrant therapy. The patient was a 75-year-old woman who presented with a right breast lump. She noticed the tumor 4 years and 6 months ago, but she had not visited any hospital. However, her daughter brought her to our hospital. The tumor was 73 mm in diameter. A core needle biopsy for breast tumor led to a diagnosis of an invasive ductal carcinoma, positive for estrogen receptor (ER) and progesterone receptor (PgR), and negative for HER2/neu. The Ki-67 positive cell index was 20%. We performed a wholebody checkup, and confirmed the diagnosis as T4cN1M0, Stage IB. She initiated endocrine therapy by letrozole (2.5 mg/day). After 1 year and 6 months, tumor marker levels increased. We changed the endocrine therapy to fulvestrant (500 mg/month). For the next 2 years and 6 months, this therapy was effective. Her axillary lymph node metastases disappeared and tumor size decreased (60%). She underwent muscle-preserving mastectomy plus axillary lymph node dissection. The pathological diagnosis from the resected surgical specimen was confirmed as invasive ductal carcinoma, positive for ER and PgR, and negative for HER2/neu protein expression. The surgical margins were negative, and there was no metastasis in the lymph nodes. She was administered adjuvant endocrine therapy. Four years after surgery, she was well without metastasis.
KW - Advanced breast cancer
KW - Elderly breast cancer
KW - Fulvestrant
UR - http://www.scopus.com/inward/record.url?scp=85043445009&partnerID=8YFLogxK
M3 - Review article
C2 - 29362313
AN - SCOPUS:85043445009
SN - 0385-0684
VL - 45
SP - 76
EP - 78
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 1
ER -